GlassScriptPhysician profile
Brian N Huh
NPI 1275614455
$90,759.84
in general payments reported to CMS, 2019-2025
32 companies · $2,585 in 2025
The $2,585 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $11K · 2021: $17K · 2022: $6,423 · 2023: $1,930 · 2024: $2,207 · 2025: $2,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,676 · Education: $47.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,675.88 |
| Education | $47.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $53,032.35 | 2019-2025 | Enbrel, Otezla, Evenity |
| Genzyme Corporation | $13,454.88 | 2019-2025 | |
| Regeneron Pharmaceuticals, INC. | $6,668.63 | 2019 | |
| Abbvie INC. | $4,107.51 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $3,476.42 | 2019 | |
| Pfizer INC. | $1,593.04 | 2019-2025 | |
| Ucb, INC. | $1,583.43 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,249.13 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Glaxosmithkline, LLC. | $925.22 | 2019-2025 | Benlysta |
| Alexion Pharmaceuticals, INC. | $887.35 | 2019-2025 | Strensiq |
| Lilly USA, LLC | $753.60 | 2019-2023 | Taltz |
| Zimmer Biomet Holdings, INC. | $528.68 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $322.89 | 2021-2024 | Saphnelo |
| Ferring Pharmaceuticals INC. | $266.22 | 2019-2023 | Euflexxa |
| Novartis Pharmaceuticals Corporation | $264.42 | 2019-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $238.68 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $205.39 | 2019 | |
| Aurinia Pharma U.S., INC. | $166.64 | 2021-2023 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $145.71 | 2022-2025 | Acthar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.49 | 2019 | |
| Amarin Pharma, INC. | $125.64 | 2019 | |
| Horizon Therapeutics Plc | $114.69 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.46 | 2019-2025 | Ofev |
| Ani Pharmaceuticals, INC. | $80.56 | 2024 | Purified Cortrophin Gel |
| Sobi, INC | $76.62 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $76.20 | 2019 | |
| Celltrion USA INC. | $47.04 | 2023 | Yuflyma |
| Genentech USA, INC. | $46.67 | 2019 | |
| Shire North American Group INC | $35.16 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.82 | 2021-2022 | |
| Almatica Pharma LLC | $18.20 | 2024 | Teriparatide |
| Depuy Synthes Sales INC. | $13.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Huh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.